Navigation Links
Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting
Date:9/25/2007

HORSHAM, Pa., Sept. 25 /PRNewswire/ -- Findings from an international, multicenter, randomized, double-blind, placebo-controlled Phase 3 trial evaluating ustekinumab (CNTO 1275) in the treatment of moderate to severe plaque psoriasis will be presented for the first time at the 21st meeting of the World Congress of Dermatology, which takes place from Sept. 30 to Oct. 5, 2007 in Buenos Aires, Argentina.

The presentation, entitled CNTO 1275 (anti-IL-12/23p40) Treatment of Psoriasis: Phase 3 Trial Results will take place on Wednesday, Oct. 3, 2007 from 11 a.m. to 1 p.m. local time (GMT +3:00; 10:00 a.m. to 12:00 p.m. EDT), Room A, La Rural Convention Center, Buenos Aires, Argentina.

These first reported findings will be the subject of a live press briefing and webcast, which will be broadcast from the World Congress of Dermatology on Wednesday, Oct. 3 at 2 p.m. EDT. Media and analysts are invited to register at http://www.CNTO1275WCD.com and listen live on Oct. 3 as investigators from the trial will review and discuss the data.

About Ustekinumab

Ustekinumab is a new, fully-human monoclonal antibody in Phase 3 development by Centocor, Inc. for the treatment of moderate to severe plaque psoriasis and is being investigated as an infrequently-administered subcutaneous injection. Ustekinumab is a novel biologic therapy that targets interleukin 12 (IL-12) and interleukin 23 (IL-23), naturally occurring proteins that are important in normalizing the immune system and that are also believed to play a role in immune-mediated inflammatory diseases.

Centocor discovered ustekinumab and has exclusive marketing rights to the product in the United States. Janssen-Cilag companies will market ustekinumab in all countries outside of the United States.

About Psoriasis

Psoriasis is a chronic, immune-mediated disease that results from inflammation in the skin and overproduction of skin ce
'/>"/>

SOURCE Centocor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
2. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
3. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
4. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
5. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
6. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
7. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
8. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
9. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
10. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
11. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... , Feb. 26, 2015 Every year ... research to fight heart disease.  Nevertheless, year after year ... ElectroCardioGrams (EKG) as the first test to determine the ... have chest pain or not, even though that technology ... despite the fact that doctors know, (while most patients ...
(Date:2/26/2015)... Mass. , Feb. 26, 2015  Spring ... novel therapeutics for the treatment of Hepatitis B ... the closing of a $22 million financing. Funds ... SB 9200, a novel, broad spectrum antiviral agent ... nucleic acid hybrid (SMNH) chemistry platform, into Phase ...
(Date:2/26/2015)... 26, 2015  Lyric Pharmaceuticals Inc. today announced the ... $20.4 million. The financing, co-led by RiverVest Venture Partners, ... Aperture Venture Partners. Lyric is a ... Wurtman , M.D., M.B.A., President & Chief Executive Officer ... Officer.  In 2014, Lyric closed a seed financing round ...
Breaking Medicine Technology:National Heart Health Month In February 2Spring Bank Pharmaceuticals Completes $22 Million Financing 2
... NEW YORK, Sept. 13, 2011 IMMUNE ... based Therapeutics for the treatment of inflammatory diseases and ... M.D., Ph.D., to the position of Chief Medical Officer.  ... pivotal  role in the development of Bertilimumab, IMMUNE,s phase ...
... DIEGO, Sept. 13, 2011 Sequenom, Inc. (NASDAQ: ... solutions, today announced the Company,s participation at the UBS Global ... in New York City September 19-21, 2011. ... Development, will present on Monday, September 19, 2011 beginning at ...
Cached Medicine Technology:IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer 2IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer 3Sequenom Announces Participation at UBS Global Life Sciences Conference 2
(Date:2/27/2015)... 27, 2015 The decision to relocate US ... facilities and to make camp more accessible to campers outside ... a Contact Football Camp. The fields are in premier condition ... country,” states Mike de Surville, vice president of US Sports ... of experienced coaches with the passion to create a program ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 RDI-Engineering will ... Mind: Pi Day event on March 14, at Moreno ... services, demonstrations on how to use engineering software and ... will be hosted by Moreno Valley College’s Upward Bound ... Success Center (SSC) in hopes to encourage students to ...
(Date:2/27/2015)... 27, 2015 Is it reasonable – and ... practices and games, and possible to do so without causing ... sports might be at high risk for concern and could ... the issues being addressed by two introductory bills, Int. ... hearing last month in New York City. More specifically, ...
(Date:2/27/2015)... February 27, 2015 Many mattresses ... people’s health. Mercola.com has introduced organic cotton mattresses ... toxic flame retardant chemicals. Dr. Mercola’s Healthy Home ... and better materials. Organic cotton is significantly less ... organic bedding products are made by Naturepedic and ...
(Date:2/27/2015)... According to a Feb. 12, 2015 news release ... treat cancer by killing cancer stem cells, has received orphan ... for use in the treatment of mesothelioma.* According to the ... encourage the development of drugs for the treatment of rare ... decision,” said Melinda Helbock, Founder of The Law Office of ...
Breaking Medicine News(10 mins):Health News:US Sports Camps Football Camps Announce New Contact Football Camp Northeast Location 2Health News:RDI-Engineering Participates in STEM”U”LATE Your Mind Event to Host Educational Exhibition 2Health News:NYSATA Athletic Trainers Provide Expert Testimony at NYC Youth Concussion and Sports Safety Hearing 2Health News:NYSATA Athletic Trainers Provide Expert Testimony at NYC Youth Concussion and Sports Safety Hearing 3Health News:New Drug Receives FDA Approval as Orphan Drug for the Treatment of Mesothelioma 2Health News:New Drug Receives FDA Approval as Orphan Drug for the Treatment of Mesothelioma 3
... March 23 (HealthDay News) -- A new study helps ... drug therapy. Researchers at the Massachusetts General Hospital ... non-small cell lung cancer, the leading cause of cancer ... with resistance. They also confirmed resistance-related genetic changes ...
... Concordia University have pioneered a computer-based method to detect ... that may open a window on the brain,s electrical ... Detection of Epileptic Seizures," presented at the annual meeting ... the very successful application of this new seizure-detection method. ...
... in French . The human brain loses 5 ... 90 years old. While some cells are lost, the brain is ... results of her most recent clinical study published today in the ... Sylvie Belleville, PhD in neuropsychology, the principal author of this study ...
... will convene in Chicago this week to present new ... detect, treat, prevent and cure osteoarthritis (OA), which affects ... the Segal North American Osteoarthritis Workshop (SNOW) on March ... as those that follow joint trauma, obesity and the ...
... who take statin drugs commonly used to lower cholesterol ... their cancer return than patients who do not take ... March issue of the International Journal of Radiation OncologyBiologyPhysics, ... Oncology (ASTRO). , In the study, 1,681 men with ...
... March 22 (HealthDay News) -- Trauma injury patients who arrive ... no more likely to die than those who arrive on ... contrast with previous research that said patients with health emergencies ... they arrive at the hospital at night or on weekends. ...
Cached Medicine News:Health News:Lung Cancer Evolves With Treatment, Study Finds 2Health News:New way to detect epileptic seizures 2Health News:Subjects at risk of Alzheimer's may now be able to delay the onset of their first symptoms 2Health News:Researchers explore new treatments to end OA 2Health News:Trauma Patients Seem More Likely to Survive on Weekends 2
Each slide contains a gram positive control of Staphylococcus aureus ATCC ® 25923 and a gram negative control of Escherichia coli ATCC ® 25922....
Each slide contains an A.F.B. positive staining control of Mycobacterium scrofulaceum ATCC ® 19981 in simulated sputum and an A.F.B. negative staining control of Escherichia coli ATCC ® 25922...
... Plate Capability The Equalizer 384 includes ... and equal tip spacing, choice of two software ... addition, this model allows you to evenly space ... accessing many gels and for use with 384 ...
... 384 Well Plate Capability The Equalizer ... original Equalizerexpandable and equal tip spacing, choice of ... capabilities. In addition, this model allows you to ... loading and accessing many gels and for use ...
Medicine Products: